Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

OBJECTIVES: Primary * Determine the acute and chronic changes in INR in patients with advanced solid tumors treated with low-dose warfarin and vatalanib. Secondary * Determine the steady-state pharmacokinetics of this regimen in these patients. * Determine the safety and tolerability of this regimen in these patients. OUTLINE: This is a nonrandomized, open-label, multicenter study. * Pharmacokinetic (PK) phase: Patients receive oral low-dose warfarin once daily on days 1-14 and oral vatalanib once daily, 1 hour before warfarin administration, on days 2-14 in the absence of disease progression or unacceptable toxicity. * Continuation phase: Patients not experiencing a drug interaction in the PK phase continue to receive oral vatalanib and oral low-dose warfarin once daily. Patients experiencing a drug interaction (INR \> 2.0) in the PK phase receive oral vatalanib alone once daily. Continuation therapy continues indefinitely in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.